India Pharma Outlook Team | Friday, 19 April 2024
Lexaria Bioscience Corp, a proprietary drug delivery technology, declares that a sanction has been received from an independent third-party ethics review board for human pilot study #2 (the "Study"), which examined GLP-1 medications and DehydraTECH.
The process will be acted on by up to 9 sound workers and will concentrate on a solitary 7 mg portion of Rybelsus (semaglutide) against two unique, focus-matched 7 mg DehydraTECH-empowered semaglutide definitions from squashed Rybelsus.
One DehydraTECH Study arm will utilize a Rybelsus piece handled with DehydraTECH that is consistent with the US Food and Drug Administration's Inactive Ingredient Database (FDA IID), conveyed inside gulped containers. This arm will be generally like the primary DehydraTECH GLP-1 human pilot concentrating on direct that proved higher conveyance of semaglutide into blood with unrivaled blood glucose control and preferred decency over was accomplished with Rybelsus.
"I am excited about this study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1," said Chris Bunka, CEO of Lexaria. "Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry."
.jpg)
